Donor stem cells from umbilical cord or placenta for osteoarthritis
Tests the safety of donor stem cells in people with osteoarthritis.
Key facts
- Who runs it
- The Foundation for Orthopaedics and Regenerative Medicine
- Where
- Naples, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Registry title
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for OA
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 92 people, planned
- Started
- 1 Dec 2022
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional
- Treatments tested
- AlloRx
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with osteoarthritis. It tests the safety of donor stem cells from umbilical cord or placenta, given into a vein and into the joint.
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of osteoarthritis.
- Earlier treatment
- People who had an organ transplant before cannot join.
Main reasons for not taking part
- Active infection or active cancer
- Long-term failure of several organs
- Pregnancy, or women before menopause not using birth control
- Important abnormal results on lab tests before treatment
- Ongoing drug abuse or allergy to sulfur
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Diagnosis of Osteoarthritis
- Understanding and willingness to sign a written informed consent document
Who cannot take part
- Continued drug abuse
- Previous organ transplant
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety
- Hypersensitivity to sulfur
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
- Pregnancy
- Pre-menopausal women not using contraception
Where in United States
Also in 1 other country, 1 site
- Prodromos Stem Cell InstituteNaples, United StatesContact: Chadwick Prodromos, MDTaking people
About the trial
What the trial wants to find out
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.
The group in the trial
- Treatment Group (AlloRx)Treatment being tested
Intravenous infusion and intraarticular injection (total dose of 100 million cells)
Treatment: AlloRx
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis
- Plain-language title
- Donor stem cells from umbilical cord or placenta for osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 16 October 2026